Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
NEW YORK, May 03, 2017 -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held on Friday May 5, 2017 at 8:30am ET to discuss results for the first quarter of 2017 and provide a business outlook for the remainder of the year. Michael S. Weiss, Executive Chairman and Chief Executive Officer, will host the call.
To participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics First Quarter 2017 Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.
TGTX-G
Contact Jenna Bosco Vice President, Investor Relations TG Therapeutics, Inc. Telephone: 212.554.4351 Email: [email protected]
